SCHEMBL4043528

SCHEMBL4043528

COc1cc(N)cc2c1OCO2

nearest known ligand 0.57

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.57
CYP3A4 P08684 3/20 0.57
SMN1; SMN2 Q16637 1/20 0.54
ACHE P22303 1/20 0.48
POLB P06746 3/20 0.45
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
ALKBH5 Q6P6C2 1/20 0.44
LMNA P02545 1/20 0.42
HPGD P15428 1/20 0.42
PKM P14618 1/20 0.42
HSD17B10 Q99714 1/20 0.42
ALOX15 P16050 1/20 0.41
GSK3B P49841 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12184928 0.85 PLK1 (0.53) ALDH1A1CYP3A4SMN1; SMN2ACHEPOLB
SCHEMBL5387246 0.79 CYP3A4 (0.58) ALDH1A1CYP3A4SMN1; SMN2ACHEPOLB
SCHEMBL10025891 0.79 CYP3A4 (0.58) ALDH1A1CYP3A4SMN1; SMN2ACHEPOLB
SCHEMBL8144226 0.78 CYP3A4 (0.57) ALDH1A1CYP3A4SMN1; SMN2ACHEPOLB
SCHEMBL5233561 0.78 CYP3A4 (0.57) ALDH1A1CYP3A4SMN1; SMN2ACHEPOLB
SCHEMBL7710239 0.78 CYP3A4 (0.58) ALDH1A1CYP3A4SMN1; SMN2ACHEPOLB
SCHEMBL14337774 0.78 CYP3A4 (0.57) ALDH1A1CYP3A4SMN1; SMN2ACHEPOLB
SCHEMBL9781426 0.77 CYP3A4 (0.69) ALDH1A1CYP3A4SMN1; SMN2ACHEPOLB
SCHEMBL5305762 0.76 CYP3A4 (0.51) ALDH1A1CYP3A4SMN1; SMN2ACHEPOLB
SCHEMBL12118415 0.75 CYP3A4 (0.54) ALDH1A1CYP3A4SMN1; SMN2ACHEPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240368139-A1 NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. 2024-11-07 US disclosed
CN-118647610-A Novel modulators of EHMT1 and EHMT2 and therapeutic uses thereof 探戈医药股份有限公司 2024-09-13 CN disclosed
EP-4416143-A1 NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF Tango Therapeutics, Inc. (US) 2024-08-21 EP disclosed
US-20230263155-A1 5-(1H-INDOL-3-YL)-OXAZOLE, -OXADIAZOLE AND -FURAN DERIVATIVES AS ENHANCERS OF SPERM MOTILITY SPERMATECH AS (NO) 2023-08-24 US disclosed
WO-2023064586-A1 NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. (US) 2023-04-20 WO disclosed
WO-2023064586-A1 NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. (US) 2023-04-20 WO disclosed
WO-2020135489-A1 2,4-DIAMINOPYRIMIDINE DERIVATIVES 上海喆邺生物科技有限公司 2020-07-02 WO disclosed
EP-1562589-B1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMA (US) 2009-01-07 EP disclosed
US-5003091-A Preparation of 3-memory-4,5-methylenedioxybenzaldehyde RHONE-POULENC CHIMIE (FR) 1991-03-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230263155-A1 5-(1H-INDOL-3-YL)-OXAZOLE, -OXADIAZOLE AND -FURAN DERIVATIVES AS ENHANCERS OF SPERM MOTILITY NR5A1, NR1I3, NR5A2 ALDH1A1 1219/4885CYP3A4 487/4885SMN1; SMN2 2799/4885
US-20240368139-A1 NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF EHMT1, EHMT2, SHMT1 ALDH1A1 163/4885CYP3A4 4085/4885SMN1; SMN2 2791/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.